🧬 BioMed Pulse · 2026-08-13 02:01 UTC

BIOMED PULSE

August 13, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in DRC and Uganda has now surpassed 2,100 confirmed cases and 828 deaths as of July 15, 2026, making it the largest Bundibugyo outbreak on record and the dominant global health emergency. The overall mood is urgent: multiple simultaneous outbreaks across continents, active drug approvals, and promising but underreported longevity science.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC & UGANDA

• As of July 15, 2026, WHO confirms 2,124 confirmed cases and 828 deaths from Bundibugyo virus disease (BVD) in DRC, with cross-border transmission continuing into Uganda. ^[1]
• The outbreak began May 2026 in Mongbwalu Health Zone, Ituri Province, DRC, and has since expanded geographically over more than two months of sustained transmission. ^[2]
• CDC has mobilized an international Ebola response team since May 17, 2026, and enhanced airport screening at Washington-Dulles International Airport and Atlanta expanded to catch arriving travelers. ^{[3] [4]}
• The case fatality rate among confirmed cases currently exceeds 39%, placing BVD in the same lethality range as prior Ebola species outbreaks.

MPOX — RECOMBINANT STRAIN

• WHO reported in February 2026 two documented cases of a recombinant MPXV strain combining genomic elements of both clade Ib and clade IIb, a known but concerning natural viral recombination event. ^[5]
• Recombination can theoretically alter transmissibility or immune escape; WHO is monitoring the global situation and performing additional viral characterization.

CYCLOSPORIASIS — UNITED STATES

• CDC identified shredded iceberg lettuce served at Taco Bell locations as the source of Cyclospora infections across five U.S. states, with 1,644 people reported sick as of July 17, 2026. ^[6]
• The outbreak has since expanded to four additional states, with CDC and FDA investigating the lettuce supply chain. ^[7]

SALMONELLA — JALAPEÑOS

• CDC issued a food safety alert on August 5, 2026 warning of a multistate Salmonella outbreak linked to jalapeños; consumers advised to avoid the implicated product. ^[8]

WEST NILE VIRUS — UNITED STATES

• CDC reported an early and record-setting West Nile virus season as of July 1, 2026, urging Americans to protect against mosquito bites during summer gatherings. ^[9]

NIPAH VIRUS — INDIA (KERALA)

• WHO confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district, Kerala, India in June 2026; the adult male presented with neurological symptoms after onset May 30, 2026. ^[10]
• Nipah carries a fatality rate of 40-75%; WHO is monitoring for secondary cases in Kerala.

YELLOW FEVER — GLOBAL

• From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity in the Americas continued from a surge that began in 2025.

AVIAN INFLUENZA A(H9N2) — ITALY

• Italy notified WHO on March 21, 2026 of a human H9N2 case in an adult male returning from Senegal; next-generation sequencing confirmed influenza A(H9N2).
• H9N2 is a low-pathogenicity avian influenza strain that occasionally spills into humans; no evidence of human-to-human transmission in this event.

MEASLES — BANGLADESH

• WHO reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts in Bangladesh as of April 2026, a nationwide surge.

HANTAVIRUS (ANDES VIRUS) — M/V HONDIUS CRUISE SHIP

• The Andes hantavirus (ANDV) cluster linked to the M/V Hondius cruise ship has been the subject of five WHO Disease Outbreak News reports since May 2, 2026, with additional confirmed cases identified since the fourth report.
• Andes hantavirus is notable as the only hantavirus strain with documented person-to-person transmission potential.

E. COLI — FROZEN BLUEBERRIES

• CDC issued a food safety alert on July 7, 2026 warning consumers not to eat recalled frozen blueberries linked to an E. coli outbreak.

🧬 LONGEVITY & AGING

PUNICALAGIN AND BONE STEM CELL SENESCENCE

• A Europe PMC study (Wang et al., Regenerative Therapy) found that punicalagin, a polyphenol derived from pomegranate, alleviates senile osteoporosis by inhibiting senescence in bone mesenchymal stem cells via the NRF2/HO-1 antioxidant pathway.
• The finding is significant because bone mesenchymal stem cell senescence is a key driver of age-related bone loss; targeting NRF2 may offer a dietary or pharmaceutical route to slow this process.

COLLAGEN XVII AND EPIDERMAL STEM CELL PHOTOAGING

• Recombinant human collagen XVII was shown to protect epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway, according to a study published in Annals of Medicine (Wang et al.).
• Collagen XVII is a transmembrane protein that anchors epidermal stem cells to the basement membrane; its decline is associated with skin aging and hair loss.

METFORMIN AND PHYSICAL FUNCTION IN OLDER OBESE ADULTS — DEMFOS TRIAL

• The DEMFOS randomized controlled trial published in Lancet Healthy Longevity evaluated metformin added to lifestyle intervention for physical function in older adults with obesity, with Nava et al. reporting results.
• An accompanying editorial by Witham and McDonald cautions against "inflated expectations" for adjunctive metformin in obesity and frailty in older people, urging careful interpretation of effect sizes.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN AGING

• A study of two Finnish generational cohorts born 20 years apart (Lääti et al., Blood Pressure journal, August 2026) found evidence linking positive life orientation to lower blood pressure in older adults, suggesting psychological factors have measurable cardiovascular impact in aging populations.

TELOMERE REPAIR IN CANCER CELL SENESCENCE

• Salmina et al. (Nucleus, July 2026) investigated repair and misrepair of telomeric DNA in doxorubicin-treated cancer cells, showing dynamic interactions with PML nuclear bodies and lamin B1 that influence whether cells enter senescence or bypass it.
• Telomere misrepair can enable cancer cells to escape senescence-driven death, a critical mechanism in treatment resistance.

P16-INK4A DETECTION IN PANCREATIC SENESCENCE

• Pipella and Thompson (Islets, July 2026) highlighted the critical importance of antibody validation when detecting the senescence marker p16-INK4A by immunohistochemistry in pancreas tissue, identifying methodological inconsistencies that may have confounded prior studies.

CANINE EPIGENETIC AGING AND DIET

• A pilot study (Chen et al., Veterinary Record Open, August 2026) found that switching dogs to a minimally processed, human-grade diet measurably altered canine epigenetic aging clocks, suggesting diet quality can modulate methylation-based aging biomarkers even in short timeframes.

ROAM1/AMPK PATHWAY AND METABOLIC LIVER DISEASE

• Zhu et al. (Bioactive Materials, July 2026) demonstrated that targeting ROAM1 with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK to resolve metabolic dysfunction-associated steatotic liver disease (MASLD) in a preclinical model — a potentially significant intersection of metabolism and aging biology.

💊 NEW CURES & APPROVALS

ORZEYFUL (OVEPOREXTON) — TAKEDA PHARMACEUTICALS USA

• FDA granted original approval (ORIG AP) to Orzeyful, whose active ingredient is oveporexton, sponsored by Takeda Pharmaceuticals USA under NDA 220860.
• Oveporexton is an orexin receptor 2 (OX2R) agonist, a novel mechanism for treating narcolepsy type 1 (orexin deficiency); this class addresses the root neurochemical deficit rather than managing symptoms alone.

INPEFA (SOTAGLIFLOZIN) — LEXICON PHARMACEUTICALS

• FDA processed a supplemental approval (SUPPL AP) for Inpefa, active ingredient sotagliflozin, a dual SGLT1/SGLT2 inhibitor from Lexicon Pharmaceuticals under NDA 216203.
• Sotagliflozin carries cardiovascular and heart failure indications; SGLT inhibitors have emerging evidence for cardiorenal and potentially anti-aging metabolic benefits.

TRYVIO (APROCITENTAN) — IDORSIA

• FDA processed a supplemental approval for Tryvio, active ingredient aprocitentan, an endothelin receptor antagonist from Idorsia under NDA 217686, indicated for resistant hypertension.

XOLAIR (OMALIZUMAB) — GENENTECH

• Genentech received a supplemental approval (SUPPL AP) for Xolair (omalizumab), the anti-IgE monoclonal antibody, under BLA 103976.

RANOLAZINE — UMEDICA

• FDA granted original approval (ORIG AP) for a generic ranolazine (antianginal, late sodium current inhibitor) to Umedica under ANDA 214551.

LEVETIRACETAM INJECTION — BAXTER HEALTHCARE

• FDA granted original approval for injectable levetiracetam (antiepileptic) to Baxter Healthcare Corporation under ANDA 208458.

🧪 CLINICAL TRIALS

HMB PLUS VITAMIN D TO PRESERVE MUSCLE DURING SEMAGLUTIDE THERAPY IN OLDER ADULTS

• NCT07760948 is a randomized, double-blind, placebo-controlled trial evaluating daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 to preserve muscle mass, physical function, and resting metabolism in adults aged 65-85 years with type 2 diabetes newly starting semaglutide (a GLP-1 agonist associated with significant muscle loss).
• This trial directly addresses a critical clinical gap: GLP-1 receptor agonists produce weight loss but may accelerate sarcopenia in older adults, and HMB is a leucine metabolite with known anti-catabolic properties.

GOAL SETTING AND COGNITIVE HEALTH IN MIDLIFE — NCT05826379

• This trial (NCT05826379) tests whether an adaptive Fitbit-based goal-setting app can increase light-intensity physical activity in middle-aged adults with the goal of promoting cognitive health, a non-pharmacological aging intervention.

UAB ALZHEIMER'S DISEASE CENTER — TAU PET IMAGING SUBSTUDY

• NCT03809351 at the University of Alabama at Birmingham is using the PET tracer AV-1451 to quantify pathologic tau deposition and regional brain distribution in an aging cohort, correlating imaging findings with demographic and clinical data.

LEUCINE DOSE RESPONSE FOR MUSCLE MAINTENANCE DURING ALTERNATE-DAY FASTING

• NCT07583875 is investigating whether varying doses of the amino acid leucine protect muscle mass during 4-week alternate-day fasting in young men with BMI 23 kg/m2 or above, measuring body composition, blood parameters, and appetite-related markers.

INHALED AZACYTIDINE PLUS DURVALUMAB FOR EARLY-STAGE NSCLC (AZA-AEGEAN)

• NCT06694454 tests neoadjuvant inhaled azacytidine (epigenetic agent, DNA methyltransferase inhibitor) combined with platinum-based chemotherapy and durvalumab (anti-PD-L1) in operable early-stage non-small cell lung cancer, combining epigenetic priming with immunotherapy.

DEPRESCRIBING TRIAL METHODOLOGY

• Two letters published in Lancet Healthy Longevity (Hwang, Boockvar, Steinman; and Van der Linden) call for a rationale-first framework before choosing trial design in deprescribing research, relevant to polypharmacy management in aging populations.

📢 PUBLIC HEALTH

CDC VACCINES FOR CHILDREN PROGRAM — 30 YEARS

• CDC marked the 30th anniversary of the Vaccines for Children (VFC) program on August 12, 2026, which provides free vaccines to children below the federal poverty level and those without health insurance.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE SURPASSES 1 MILLION PARTICIPANTS

• CDC's voluntary air travel biosurveillance program exceeded 1 million enrolled participants as of January 2026, strengthening detection of novel pathogens entering the United States through international travel.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

• WHO certified Timor-Leste malaria-free in July 2025, crediting a concerted nationwide elimination effort begun after independence in 2002.

DRUG-RESISTANT BACTERIA SHARPLY RISING

• A September 2025 CDC report documented a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing antimicrobial resistance as a long-term public health threat.

CONGENITAL SYPHILIS — 12TH CONSECUTIVE ANNUAL INCREASE

• CDC data from September 2025 showed U.S. newborn syphilis cases increased for the 12th consecutive year in 2024, reflecting ongoing gaps in prenatal STI screening and treatment.

CDC FREE MIND CAMPAIGN FOR YOUTH

• CDC launched the Free Mind campaign on August 5, 2026, providing teens with resources about substance use and mental health, following data showing improvements in some mental health metrics but persistent risks in others.

NOTE: This briefing is informational only and does not constitute medical advice. Consult a qualified healthcare professional for personal health decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
3. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
4. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
5. Mpox: recombinant virus with genomic elements of clades Ib and… — WHO Disease Outbreak News
6. Shredded iceberg lettuce served at Taco Bell locations is sour… — CDC Newsroom
7. Cyclospora outbreak linked to iceberg lettuce expanded to four… — CDC Newsroom
8. CDC warns of <em>Salmonella</em> outbreak linked to jalapeños — CDC Newsroom
9. CDC Encourages Americans to Stay Mosquito Bite-Free during Ame… — CDC Newsroom
10. Nipah virus disease - India — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260813-02-v54 · 2026-08-13 02:01 UTC · pulse.uzylab.com